Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2020 October;155(5) > Giornale Italiano di Dermatologia e Venereologia 2020 October;155(5):658-61

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   Freefree

Giornale Italiano di Dermatologia e Venereologia 2020 October;155(5):658-61

DOI: 10.23736/S0392-0488.18.06033-9

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Survey of cutaneous adverse reactions to targeted cancer therapies: value of dermatological advice

Giovanni DAMIANI 1, 2, 3 , Ausilia MANGANONI 3, Simone CAZZANIGA 4, 5, Luigi NALDI 4, 6,, the OncoSkin working group 

1 Young Dermatologists Italian Network (YDIN), Study Center of the Italian Group for Epidemiologic Research in Dermatology (GISED), Bergamo, Italy; 2 Unit of Clinical Dermatology, Department of Biomedical, Surgical and Dental Sciences, IRCCS Galeazzi Orthopedic Institute, University of Milan, Milan, Italy; 3 Unit of Dermatology, ASST Spedali Civili of Brescia, Brescia, Italy; 4 Centro Studi GISED, Bergamo, Italy; 5 Department of Dermatology, Inselspital University Hospital, Bern, Switzerland; 6 Department of Dermatology, AULSS8, San Bortolo Hospital, Vicenza, Italy



BACKGROUND: Target-therapy offers a better efficacy for several cancers, with less toxic adverse effects, if compared with traditional chemotherapy. However cutaneous complications are increased in number and complexity. The severity of these reactions positively correlates with efficacy, and the management of these reactions is challenging.
METHODS: This was a multicenter cross-sectional study on a consecutive series of adult patients with incident cutaneous reactions linked to targeted cancer therapies observed in five referral centers for cancer treatment in the province of Bergamo and Brescia in northern Italy. Each center was asked to collect data on the first 5 consecutive cases of severe adverse cutaneous events observed during a one-week surveillance period.
RESULTS: From June to October 2012, 25 patients with cutaneous adverse reactions linked to targeted therapies were included in the study. The main prescribed drugs were cetuximab (52%) and erlotinib (20%) and the most common reactions were folliculitis/pustules (40%) and rash/erythema (40%). Hand-foot reaction syndrome was present in 8% of patients. A total of 30% of patients treated for a cutaneous reaction underwent a consultation by a dermatologist. In these patients the rate of oncologic therapy continuation without regimen modifications was higher (100%), while it was progressively lower in patients treated by oncologists (71%) or without any specific treatment (60%).
CONCLUSIONS: Adverse reaction should be recognized by both dermatologists and oncologists and a multidisciplinary approach is mandatory.


KEY WORDS: Skin; Oncologists; Dermatologists

top of page